Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.
Target Price
The average target price of ALEC is 2.1 and suggests 8% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
Buy
Sell